Project Grant R21CA301376
- This federal Project Grant award of $677,787 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of California, San Francisco (UCSF) to study the role of AIRE-expressing macrophages in tumor immune evasion. The research aims to define novel mechanisms by which tumors evade immune responses, with a focus on the function of these unique macrophage populations in the tumor microenvironment. The project will run from August 2025 through...
- This federal Project Grant award of $680,598 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to understand the role of the Cullin-5 complex in regulating T cell dysfunction in cancer. The research aims to develop new therapeutic approaches to engineer T cells with durable effector function, by targeting the Cullin-5 complex to prevent T cell dysfunction caused by chronic tumor antigen stimulation. The award was provided to the...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the University of California, San Francisco (UCSF) to genetically engineer myeloid cells, including macrophages and dendritic cells, for the treatment of solid tumors. The $0.00 award, with a project period from August 1, 2025 to July 31, 2028, aims to apply advanced genetic engineering tools to reprogram myeloid cells and enhance their tumoricidal activities and resistance to...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- The Project Grant award of $424,734 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of a novel spatial proteomics approach to profile immune cell types and their locations within a tumor microenvironment. The University of Illinois, the awardee, aims to integrate 3D microscopy techniques with bottom-up proteomic assays to offer deep proteome profiles of specific immune cells at various subregions of a mouse tumor (Aims 1 and 2). The goal is...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- This federal Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University supports research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The project aims to carry out high-throughput screens of thousands of microbial macromolecules to identify those that directly modulate macrophages, with the goal of enhancing cancer immunotherapy...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $676,006 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at early identification of resistance to immunotherapy for cancer treatment. The key products and services to be delivered under this 5-year award include: Developing and testing non-invasive imaging strategies, such as PET scans and implantable fluorescence sensors,...
- This $156,276 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The funding supports research aimed at decoding therapeutic tumor antigens and understanding how dendritic cells contribute to anti-tumor T cell immunity, with a focus on pancreatic cancer. Key objectives include comparing tumor immunopeptidomes presented by cancer cells versus dendritic cells, and evaluating the impact of regulatory T cells on...
- The National Institutes of Health (NIH) National Cancer Institute awarded a $618,928 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of California, Berkeley. The 5-year grant, awarded on June 9, 2025, will fund research to investigate the mechanisms by which regulatory T cells (Tregs) within tumors suppress antitumor immune responses. The project aims to determine if blocking Treg function solely within the tumor microenvironment is sufficient to control...
This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular immunoassay methods, the researchers will illuminate functional effector CD8 T cell states and their local microenvironmental partners. The goal is to identify critical phenotype-biology relationships that can inform the development of new ways to boost anti-tumor immunity. The project has an award period from August 8, 2025 to July 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $421.7k | 8/7/25 |